iOrganBio has announced the appointment of Jessica Owens to its Board of Directors, bringing her extensive experience in life sciences and AI to the forefront of its operations.
With over 20 years in company-building and investment, Owens is recognized for her role in co-founding GRAIL, which successfully secured over $1 billion in funding and formed strategic partnerships with major pharmaceutical companies like Bristol Myers Squibb, Merck, and Johnson & Johnson. Her expertise is expected to be crucial as iOrganBio aims to enhance its CellForge platform and expand its partnerships in the field of AI-driven cell manufacturing.
iOrganBio is focused on revolutionizing human cell production through its innovative CellForge technology, which integrates AI and automation to improve the scalability and predictability of cell therapies. The platform leverages a functional human CellAtlas, which serves as a digital reference for various cell types, thereby streamlining the development process for in vitro models and regenerative medicine.
This strategic appointment underscores the growing importance of AI in life sciences, particularly in enhancing the efficiency and quality of cell manufacturing processes. As iOrganBio continues to advance its capabilities, the integration of Owens' insights may significantly influence the future landscape of cell-based therapies and drug development.